GlaxoSmithKline plans to 'relaunch' Shingrix after the pandemic decimated sales

GlaxoSmithKline, set to unshackle itself from its consumer health business next year, plans to make vaccines a major focus for the so-called "New GSK." Blockbuster shingles vaccine Shingrix will play a key role.